Nature Medicine, Published online: 28 July 2026; doi:10.1038/s41591-026-04558-5
A phase 1/2 study found maternal hexavalent 6 polysaccharide−protein conjugate group B Streptococcus vaccine (GBS6) to be safe and immunogenic and to have induced antibody responses to vaccine serotypes in infants whose parent was vaccinated while pregnant.
